WuXi Biologics Receives Asia-Pacific Best Bioprocessing Excellence Award from IMAPAC

We are pleased to announce that WuXi Biologics  has received the 2017 Asia-Pacific Best Bioprocessing Excellence Award from IMAPAC, a leading consulting firm. WuXi Biologics has been recognized for its outstanding performance for...

WuXi AppTec Lab Testing Division’s Bioanalytical Service Unit Passed FDA Inspection

We are pleased to announce that WuXi’s  Lab Testing Division(LTD)’s Bioanalytical facility in Shanghai once again passed US FDA’s bioequivalence (BE) inspection with no 483 observations. The inspectors from FDA thoroughly audited...

WuXi AppTec Acquires Biology Focused R&D Service Leader HD Biosciences

We are excited to announce that WuXi has acquired HD Biosciences (HDB), a leading biology focused preclinical drug discovery contract research organization (CRO). After completion of acquisition, HD Biosciences will become...

Novel Anti-IL-6 Antibody For Rheumatoid Arthritis From WuXi-MedImmune (AZN) Joint Venture Receives Clinical Trial...

We are excited to announce that an Investigational New Drug (IND) application for WBP216 (MEDI5117), a novel anti-IL-6 antibody for rheumatoid arthritis (RA) and other autoimmune disorders – developed by our...

WuXi AppTec Receives Inaugural “Company of the Year” Award from BayHelix

We are honored to announce that WuXi has received the inaugural “Company of the Year” Award from BayHelix. The award is part of the BayHelix China Healthcare Awards series, celebrating outstanding...

SPOTLIGHT

STAY CONNECTED

Twitter LinkedIn 

INNOVATION THAT MATTERS